European MidPharmas are a class of companies that Novasecta has been working with intensively since its foundation. These R&D-based pharmaceutical companies with annual revenues of €50m to €5bn are tremendously diverse, just like the European countries in which they are based. Working closely with such companies for over a decade has provided us with a unique perspective and a substantial body of practical insight into how pharmaceutical and biotech companies of all sizes can survive and thrive.
What our clients
say about us
We have worked collaboratively with Novasecta over many years across a range of strategic topics. I have particularly valued how they really understand and care about our business, and how they manage to apply their deep industry insights to our context. This has brought my Management Team and Board to clarity and alignment on practical strategic moves at important moments in our evolution as a company.CEO – Biotech